|
A case control study of sarcosine as an early prostate cancer detection biomarker.
|
26429735
|
BMC Urol
|
|
A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment.
|
27431498
|
Prostate Cancer Prostatic Dis.
|
|
A genome-wide association study of prostate cancer in Latinos.
|
31226226
|
Int. J. Cancer
|
|
A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.
|
23232570
|
Adv Anat Pathol
|
|
A simple-to-use method incorporating genomic markers into prostate cancer risk prediction tools facilitated future validation.
|
25684153
|
J Clin Epidemiol
|
|
Active surveillance for prostate cancer.
|
21119090
|
JAMA
|
|
Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
|
25636657
|
J. Urol.
|
|
Addressing overdiagnosis and overtreatment in cancer: a prescription for change.
|
24807866
|
Lancet Oncol.
|
|
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
|
21350221
|
J. Natl. Cancer Inst.
|
|
Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests.
|
22846433
|
J Proteomics
|
|
Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests.
|
22846433
|
J Proteomics
|
|
Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men.
|
12394768
|
J. Urol.
|
|
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.
|
16622122
|
J. Natl. Cancer Inst.
|
|
Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men.
|
16406987
|
J. Urol.
|
|
Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men.
|
19528667
|
Carcinogenesis
|
|
Association of polymorphisms in TGFB1 and prostate cancer prognosis.
|
18082198
|
J. Urol.
|
|
Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans.
|
17908993
|
Clin. Cancer Res.
|
|
Biomarker-based methods for determining noncompliance in a prevention trial.
|
12505245
|
Control Clin Trials
|
|
Biomarkers for prostate cancer detection.
|
17936845
|
J. Urol.
|
|
Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
|
20142396
|
Am. J. Epidemiol.
|
|
Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening.
|
20739049
|
Urology
|
|
Characterization of PacMetUT1, a recently isolated human prostate cancer cell line.
|
18361412
|
Prostate
|
|
CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians.
|
18544568
|
Carcinogenesis
|
|
Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridization.
|
16618725
|
Cancer Res.
|
|
DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
|
26332453
|
Prostate
|
|
Erectile dysfunction and subsequent cardiovascular disease.
|
16414947
|
JAMA
|
|
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population.
|
17169636
|
Urology
|
|
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
|
17437804
|
J. Urol.
|
|
Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making.
|
25090603
|
JAMA
|
|
Future directions in the prevention of prostate cancer.
|
24281061
|
Nat Rev Clin Oncol
|
|
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent.
|
23476788
|
Prostate Cancer
|
|
Helicobacter Pylori Infection in Texas Hispanic and Non-Hispanic White Men: Implications for Gastric Cancer Risk Disparities.
|
28413904
|
Am J Mens Health
|
|
Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR study.
|
30385837
|
Prostate Cancer Prostatic Dis.
|
|
Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort.
|
27635949
|
Am. J. Surg. Pathol.
|
|
Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators.
|
25989018
|
J Biomed Inform
|
|
Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.
|
29422418
|
Eur Urol Focus
|
|
Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening.
|
25686543
|
J. Urol.
|
|
Is there a role for body mass index in the assessment of prostate cancer risk on biopsy?
|
24747090
|
J. Urol.
|
|
Lack of disparity in lower urinary tract symptom severity between community-dwelling non-Hispanic white, Mexican-American, and African-American men.
|
17445654
|
Urology
|
|
Limited PSA testing in indigent men in South Texas: an appropriate care or missing a prevention opportunity?
|
22822113
|
Cancer Epidemiol. Biomarkers Prev.
|
|
Multiplexed targeted mass spectrometry assays for prostate cancer-associated urinary proteins.
|
29254211
|
Oncotarget
|
|
Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer.
|
25065737
|
Prostate
|
|
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
|
15998892
|
JAMA
|
|
Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator.
|
25819722
|
Eur. Urol.
|
|
Predicting prostate cancer risk through incorporation of prostate cancer gene 3.
|
18707724
|
J. Urol.
|
|
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
|
17634486
|
J. Clin. Oncol.
|
|
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
|
15163773
|
N. Engl. J. Med.
|
|
Processing of voided urine for prostate cancer RNA biomarker analysis.
|
26306723
|
Prostate
|
|
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.
|
21074193
|
J. Urol.
|
|
Prostate cancer detection strategies.
|
16630521
|
Curr Urol Rep
|
|
Prostate cancer detection: a view of the future.
|
21130561
|
Eur. Urol.
|
|
Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.
|
24862395
|
Urology
|
|
Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.
|
17991549
|
Urology
|
|
Prostate-specific antigen in the early detection of prostate cancer.
|
17576986
|
CMAJ
|
|
Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studies.
|
17405989
|
J. Natl. Cancer Inst.
|
|
Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.
|
15329895
|
Cancer
|
|
Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine.
|
18030357
|
Neoplasia
|
|
Relationship of body mass index and prostate specific antigen in a population-based study.
|
15082010
|
Urol. Oncol.
|
|
Relationship of body mass index and prostate specific antigen in a population-based study.
|
15082010
|
Urol. Oncol.
|
|
Rethinking screening for breast cancer and prostate cancer.
|
19843904
|
JAMA
|
|
Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis.
|
19683737
|
J. Urol.
|
|
Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer.
|
26979652
|
J. Urol.
|
|
Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
|
19475640
|
Prostate
|
|
Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer.
|
15258333
|
Dis. Markers
|
|
Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer.
|
19505920
|
Cancer Epidemiol. Biomarkers Prev.
|
|
Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men.
|
20086112
|
Cancer Epidemiol. Biomarkers Prev.
|
|
Temporal changes in the clinical approach to diagnosing prostate cancer.
|
23271768
|
J. Natl. Cancer Inst. Monographs
|
|
The association of body mass index and prostate-specific antigen in a population-based study.
|
15668913
|
Cancer
|
|
The diagnostic value of adiponectin multimers in healthy men undergoing screening for prostate cancer.
|
24296854
|
Cancer Epidemiol. Biomarkers Prev.
|
|
The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology.
|
15283893
|
Urol. Oncol.
|
|
The Early Detection Research Network's Specimen reference sets: paving the way for rapid evaluation of potential biomarkers.
|
23193062
|
Clin. Chem.
|
|
The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.
|
23313212
|
J. Urol.
|
|
The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape.
|
25636656
|
J. Urol.
|
|
Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study.
|
27810448
|
J. Urol.
|
|
Total prostate specific antigen stability confirmed after long-term storage of serum at -80C.
|
18550121
|
J. Urol.
|
|
Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry.
|
29117387
|
J. Natl. Cancer Inst.
|
|
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
|
23515404
|
Clin. Cancer Res.
|
|
Urine metabolomics analysis for kidney cancer detection and biomarker discovery.
|
19008263
|
Mol. Cell Proteomics
|
|
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection.
|
19836788
|
J. Urol.
|
|
Validation of genome-wide prostate cancer associations in men of African descent.
|
21071540
|
Cancer Epidemiol. Biomarkers Prev.
|
|
Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI.
|
31639607
|
Cancer Epidemiol
|
|
VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.
|
18483391
|
Clin. Cancer Res.
|
|
What do the screening trials really tell us and where do we go from here?
|
24725484
|
Urol. Clin. North Am.
|
|
Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population.
|
19286205
|
J. Urol.
|
